Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide

91Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

Abstract

The peptide hormone relaxin is a potent vasodilator with therapeutic potential in diseases complicated by vasoconstriction, including heart failure. However, the molecular mediators and magnitude of vasodilation may vary according to duration of exposure and artery type. The objective of these studies was to determine mechanisms of rapid (within minutes) relaxin-induced vasodilation and to examine whether relaxin dilates arteries from different animal species and vascular beds. Rat and mouse small renal, rat mesenteric, and human sc arteries were isolated, mounted in a pressure arteriograph, and treated with recombinant human relaxin (rhRLX; 1-100 ng/ml) after preconstriction with phenylephrine. Rat and mouse small renal as well as human sc arteries dilated in response to rhRLX, whereas rat mesenteric arteries did not. Endothelial removal or pretreatment with L-NG-monomethyl arginine (L-NMMA) abolished rapid relaxin-induced vasodilation; phosphatidylinositol-3-kinase (PI3K) inhibitors also prevented it. In cultured human endothelial cells, rhRLX stimulated nitric oxide (assessed using 4-amino-5-methylamino-2′7′-difluorofluorescein) as well as Akt and endothelial NO synthase (eNOS) phosphorylation by Western blotting but not increases in intracellular calcium (evaluated by fura-2). NO production was attenuated by inhibition of Gαi/o and Akt (using pertussis toxin and the allosteric inhibitor MK-2206, respectively), PI3K, and NOS. Finally, the dilatory effect of rhRLX in rat small renal arteries was unexpectedly potentiated, rather than inhibited, by pretreatment with the vascular endothelial growth factor receptor inhibitor SU5416. We conclude that relaxin rapidly dilates select arteries across a range of species. The mechanism appears to involve endothelial Gαi/o protein coupling to PI3K, Akt, and eNOS but not vascular endothelial growth factor receptor transactivation or increased calcium. Copyright © 2011 by The Endocrine Society.

References Powered by Scopus

Activation of nitric oxide synthase in endothelial cells by Akt- dependent phosphorylation

3158Citations
N/AReaders
Get full text

MK-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

787Citations
N/AReaders
Get full text

Activation of orphan receptors by the hormone relaxin

715Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Relaxin family peptides and their receptors

428Citations
N/AReaders
Get full text

Maternal vasodilation in pregnancy: The emerging role of relaxin

167Citations
N/AReaders
Get full text

Cardiac endothelium-myocyte interaction: Clinical opportunities for new heart failure therapies regardless of ejection fraction

120Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

McGuane, J. T., Debrah, J. E., Sautina, L., Jarajapu, Y. P. R., Novak, J., Rubin, J. P., … Conrad, K. P. (2011). Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology, 152(7), 2786–2796. https://doi.org/10.1210/en.2010-1126

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 19

54%

Professor / Associate Prof. 10

29%

Researcher 6

17%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 16

46%

Medicine and Dentistry 16

46%

Pharmacology, Toxicology and Pharmaceut... 2

6%

Veterinary Science and Veterinary Medic... 1

3%

Save time finding and organizing research with Mendeley

Sign up for free